ZINFORO® has proven clinical efficacy across 6 Phase III, randomised, controlled, double-blind trials in adult patients with CAP and cSSTI.1-6
In the CANVAS 1 and CANVAS 2 studies, ZINFORO® was as effective as vancomycin plus aztreonam in adult patients with cSSTI1,*:
Header | ||
---|---|---|
Header | Header | Header |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
The lower limit of the 95% CI for the treatment difference was above –10%, which met the predefined criteria for non-inferiority.1
*There is no experience with ZINFORO® in the treatment of cSSTI in the following patient groups: The immunocompromised, patients with severe sepsis/septic shock, necrotising fasciitis, perirectal abscess and patients with third-degree and extensive burns. There is limited experience in treating patients with diabetic foot infections. Caution is advised when treating such patients.7
There was a trend towards early clinical response at Day 32,*:
*ZINFORO® was associated with a non-statistically significant early clinical response defined by the cessation of spread and absence of fever.2
CANVAS, CeftAroliNe fosamil vs Vancomycin in Skin and skin structure infection; CAP, community-acquired pneumonia; CE, clinically evaluable; CI, confidence interval; cSSTI, complicated skin and soft-tissue infection; MRSA, methicillin-resistant Staphylococcus aureus; q12h, every 12 hours.
References:
Simple dosing with a flexible infusion time
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.